🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

Reckitt expects U.S. infant formula shortage until spring

Published 12/01/2022, 07:45 AM
Updated 12/02/2022, 12:01 PM
© Reuters. FILE PHOTO: Mead Johnson's product Enfamil baby formula are displayed on a store shelf in New York City, U.S., February 10, 2017. REUTERS/Brendan McDermid
TGT
-
ABT
-
WBA
-
PRGO
-

By Richa Naidu

LONDON (Reuters) -The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to "persist" until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil. Panicked parents had earlier this year emptied the baby formula aisles at supermarkets after former top U.S. manufacturer Abbott Laboratories (NYSE:ABT) in February recalled dozens of types of its Similac, Alimentum and EleCare formulas.

The products, made at a plant in Michigan, were pulled after complaints of bacterial infections. Supermarkets like Target (NYSE:TGT) and Walgreens Boots Alliance (NASDAQ:WBA) were forced to limit sales, putting pressure on the Biden administration to address the crisis.

The White House in May took steps to address the shortage, invoking the Defense Production Act to help manufacturers obtain the ingredients needed to ramp up supply.

Supplies are yet to return to normal since the peak of the crisis in May and June, despite the U.S. making progress in replenishing stocks, said Robert Cleveland, Reckitt senior vice president of North America and Europe Nutrition.

"I suspect that will persist to some degree until the spring resets," he said. The situation was improving, he said however. “There is much more volume on shelves than a few months ago, and enough to feed America’s babies."

New brands have increased formula supply this year, with multiple foreign brands available on shelves and online, including Danone's Aptamil and Bellamy's Organic, a White House official said.

"We are in close touch with top retailers who continue to have supplies of formula on hand, but may still lack all the sizes and varieties they once carried," the official said, adding that industry data shows U.S. formula production so far this year has outpaced 2021 levels.

According to data firm IRI, in-stock rates at U.S. stores have continued to improve and are close to pre-recall levels at 86% now versus 88–90% prior to the recall.

Rival manufacturers Perrigo Company (NYSE:PRGO) Plc and Danone declined to comment.

Since the Abbott recall, Reckitt's share of the infant formula market has skyrocketed, making it the No.1 supplier in the United States.

The British company has yet to see its newfound popularity recede, with Cleveland saying its just over 50% market share has "remained relatively unchanged" since earlier this year.

Its position has been further boosted by the United States saying it will temporarily cover the cost of baby formula for low-income families dependent on government discounts in states contracted with the company.

Companies normally bid for state contracts to be the sole provider of baby formula for low-income families under the Women, Infants and Children (WIC) programme. In their bids, they offer a "rebate" in the form of discounts to the states.

The government's intervention, aimed at incentivising firms to boost supplies, effectively covers that rebate.

Reckitt has said its formula factories are operating 24/7, and that it was feeding more than 40% of all low-income WIC infants.

© Reuters. FILE PHOTO: Mead Johnson's product Enfamil baby formula are displayed on a store shelf in New York City, U.S., February 10, 2017. REUTERS/Brendan McDermid

"Certainly at some point in the future, we expect they (the United States Department of Agriculture) will want to return the programme to normal," Cleveland said.

"What we're telling them is to give us enough notice - to put, essentially, a date on the calendar.... don't try to shock the system by making it happen too quickly - give us time to adjust because we'll have to adjust our production, we'll have to adjust our distribution," he said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.